{"drugs":["Azilsartan Medoxomil","Edarbi"],"mono":{"0":{"id":"929810-s-0","title":"Generic Names","mono":"Azilsartan Medoxomil"},"1":{"id":"929810-s-1","title":"Dosing and Indications","sub":[{"id":"929810-s-1-4","title":"Adult Dosing","mono":"<b>Hypertension:<\/b> 80 mg ORALLY once daily; consider a starting dose of 40 mg ORALLY once daily for patients receiving high doses of diuretics "},{"id":"929810-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"929810-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatric:<\/b> No dosage adjustment necessary<\/li><li><b>renal impairment, mild to severe or ESRD:<\/b> No dosage adjustment necessary<\/li><li><b>hepatic dysfunction, mild to moderate:<\/b> No dosage adjustment necessary<\/li><li><b>volume- and salt-depleted patients, and patients under treatment with high doses of diuretics:<\/b> 40 mg ORALLY once daily<\/li><\/ul>"},{"id":"929810-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hypertension<br\/>"}]},"2":{"id":"929810-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Discontinue use of azilsartan medoxomil as quickly as possible if pregnancy is detected as drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.<br\/>"},"3":{"id":"929810-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929810-s-3-9","title":"Contraindications","mono":"concomitant use with aliskiren in diabetic patients.<br\/>"},{"id":"929810-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- discontinue use as soon as possible if pregnancy is detected<\/li><li>-- concomitant use agents that affect the renin-angiotensin system may cause fetal injury or death<\/li><li>Cardiovascular:<\/li><li>-- increased risk of symptomatic hypotension in patients with volume and\/or salt depletion; correct prior to initiating therapy or reduce dose<\/li><li>Renal:<\/li><li>-- increased risk of oliguria, progressive azotemia, and rarely, acute renal failure and\/or death in patients with severe congestive heart failure, renal artery stenosis, with volume depletion, and in patients whose renal function is dependent on the renin-angiotensin system<\/li><li>-- increase serum creatinine or BUN may occur in patients with unilateral or bilateral renal artery stenosis<\/li><li>Reproductive:<\/li><li>-- use during second or third trimester of pregnancy may cause fetal and neonatal morbidity and death; discontinue therapy as soon as possible when pregnancy is detected<\/li><li>-- monitoring required, due to potential harm to the fetus, in pregnant patients where no alternative therapy can be found; discontinue therapy if oligohydramnios is observed, unless therapy is lifesaving for the mother<\/li><li>Concomitant use:<\/li><li>-- avoid concomitant use of renin-angiotensin system inhibitors<\/li><li>-- avoid concomitant use with aliskiren in patients with renal impairment (glomerular filtration rate less than 60 mL\/min)<\/li><\/ul>"},{"id":"929810-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"929810-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929810-s-4","title":"Drug Interactions","sub":[{"id":"929810-s-4-13","title":"Contraindicated","mono":"<ul>Aliskiren (probable)<\/ul>"},{"id":"929810-s-4-14","title":"Major","mono":"<ul><li>Benazepril (established)<\/li><li>Captopril (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosinopril (established)<\/li><li>Lisinopril (established)<\/li><li>Lithium (theoretical)<\/li><li>Moexipril (established)<\/li><li>Nitisinone (theoretical)<\/li><li>Perindopril (established)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Trandolapril (established)<\/li><li>Trimethoprim (theoretical)<\/li><\/ul>"},{"id":"929810-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Clonixin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sulindac (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Valdecoxib (probable)<\/li><\/ul>"}]},"5":{"id":"929810-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Diarrhea (up to 2%)<br\/><b>Serious<\/b><br\/><b>Renal:<\/b>Renal failure<br\/>"},"6":{"id":"929810-s-6","title":"Drug Name Info","sub":{"0":{"id":"929810-s-6-17","title":"US Trade Names","mono":"Edarbi<br\/>"},"2":{"id":"929810-s-6-19","title":"Class","mono":"<ul><li>Angiotensin II Receptor Antagonist<\/li><li>Antihypertensive<\/li><\/ul>"},"3":{"id":"929810-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929810-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929810-s-7","title":"Mechanism Of Action","mono":"Azilsartan medoxomil is a prodrug which is hydrolyzed to azilsartan in the gastrointestinal tract. The active moiety, azilsartan, is an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptors. By blocking the binding of angiotensin II to the AT1 receptors, azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II and therefore promotes vasodilation and decreased aldosterone effects. Azilsartan displays greater than 10,000-fold affinity for AT1 receptor, compared with binding to AT2 receptor, and has not shown affinity to any other receptors or ion channels of cardiac significance. The breakdown of bradykinin appears unaffected by azilsartan.<br\/>"},"8":{"id":"929810-s-8","title":"Pharmacokinetics","sub":[{"id":"929810-s-8-23","title":"Absorption","mono":"<ul><li>Tmax: 1.5 to 3 hours<\/li><li>Bioavailability, azilsartan: 60%<\/li><li>Effect of food: no effect on bioavailability<\/li><\/ul>"},{"id":"929810-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, Albumin: greater than 99%<\/li><li>Vd: 16 L<\/li><\/ul>"},{"id":"929810-s-8-25","title":"Metabolism","mono":"Liver, via CYP2C9 <br\/>"},{"id":"929810-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: 2.3 mL\/min<\/li><li>Renal excretion: 42%, 15% unchanged<\/li><li>Fecal: 55%<\/li><\/ul>"},{"id":"929810-s-8-27","title":"Elimination Half Life","mono":"11 hours <br\/>"}]},"9":{"id":"929810-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with or without food<\/li><li>dispense and store in original container<\/li><\/ul>"},"10":{"id":"929810-s-10","title":"Monitoring","mono":"<ul><li>blood pressure to assess clinical response<\/li><li>renal function; particularly in patients with renal impairment<\/li><\/ul>"},"11":{"id":"929810-s-11","title":"How Supplied","mono":"<b>Edarbi<\/b><br\/>Oral Tablet: 40 MG, 80 MG<br\/>"},"13":{"id":"929810-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as this medicine may cause dizziness.<\/li><li>Drug may cause diarrhea, nausea, hypotension, cough, or fatigue.<\/li><li>Patients should keep this drug in its original container from the manufacturer, to protect against degradation due to light and moisture.<\/li><\/ul>"}}}